Agreement with Maastricht University

Glucox Biotech has signed an agreement with Prof. Harald Schmidt of Maastricht University for further development of Glucox´ lead compound for treatment of ischemic stroke.

It has recently been shown that NOX4 is an effective therapeutic target in acute stroke. Prof. Harald Schmidt and his team have convincingly shown that significant increase in NOX4 activity is a main component in neuronal cell death that occurs in ischemic stroke. Within the collaboration Prof. Schmidt and co-workers will evaluate Glucox’ NOX4 inhibitors for further development into pharmaceuticals that will prevent neuronal cell death in ischemic stroke.

Ref: Radermacher, K., A., et al (2012) Experimental & Translational Stroke Medicine, 4:11 doi: 10.1186/2040-7378-4-11